Skip to main content

Redmile Group, LLC

13F filer · CIK 0001425738
Reported Aug 14, 2026
Net seller this quarter
13F portfolio value$1.49BU.S. long equity reported on 13F
Positions394 new · 0 closed
Net flow last quarter-$345MBuys minus sells
Top 10 positions weight73.5%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 14, 202639 positions
SRRKScholar Rock Holding Corp$237M15.92%3.55%-52.5%Q2 2018
KRYSKrystal Biotech, Inc.$235M15.77%2.14%-6.2%Q4 2018
STOKStoke Therapeutics, Inc.$129M8.67%6.32%-5.2%Q2 2019
IMNMImmunome Inc.$104M6.99%4.33%-11.6%Q4 2023
NRIXNurix Therapeutics, Inc.$98.8M6.64%3.93%-47.3%Q3 2020
ABSIAbsci Corp$78.1M5.24%4.32%-18.3%Q3 2021
ANNXAnnexon, Inc.$67.8M4.55%7.95%-18.4%Q3 2020
RGNXREGENXBIO Inc.$52.3M3.51%8.07%Not reportedQ3 2015
STTKShattuck Labs, Inc.$47.8M3.21%6.84%+24.4%Q4 2020
NGNENeurogene Inc.$44.4M2.98%8.92%-3.3%Q4 2023
BEAMBeam Therapeutics Inc.$40M2.68%1.13%-5.9%Q1 2020
AGMBAgomab Therapeutics NV$35.5M2.38%8.00%+1649.7%Q1 2026
FATEFate Therapeutics Inc$34.8M2.33%11.03%Not reportedQ2 2015
IDYAIDEAYA Biosciences, Inc.$23.9M1.60%0.66%+22.9%Q4 2023
SLNSilence Therapeutics plc$23.8M1.60%1.53%Not reportedQ1 2024
COGTCogent Biosciences, Inc.$19.5M1.31%0.29%-26.9%Q2 2023
SLDBSolid Biosciences Inc.$19.5M1.31%1.85%-3.1%Q4 2024
NUVBNuvation Bio Inc.$17.2M1.16%0.87%-3.9%Q1 2021
CLDXCelldex Therapeutics, Inc.$16.1M1.08%0.55%+65.9%Q4 2013
CLYMClimb Bio, Inc.$16M1.07%2.14%NewQ2 2026
ALXOAlx Oncology Holdings Inc$15.3M1.03%5.35%-7.2%Q3 2020
BMRNBiomarin Pharmaceutical Inc$15.2M1.02%0.14%+52.5%Q2 2014
XENEXenon Pharmaceuticals Inc.$13.8M0.93%0.24%-12.7%Q2 2022
ZYMEZymeworks Inc.$12.9M0.86%0.69%Not reportedQ1 2020
ADCTADC Therapeutics SA$12.3M0.83%9.04%-25.5%Q2 2020
AURAAura Biosciences, Inc.$11.8M0.79%1.61%NewQ2 2026
ODTXOdyssey Therapeutics, Inc.$7.95M0.53%0.89%NewQ2 2026
LIVNLivaNova PLC$7.66M0.51%0.17%-14.0%Q2 2017
ESTAEstablishment Labs Holdings Inc.$7.63M0.51%0.30%-14.0%Q3 2018
CBLLCeribell, Inc.$7.52M0.51%1.01%Not reportedQ4 2024
DBVTDBV Technologies S.A.$6.73M0.45%0.14%-16.5%Q3 2015
INSMINSMED Inc$5.46M0.37%0.02%Not reportedQ3 2014
PRMEPrime Medicine, Inc.$5.13M0.34%0.77%-12.7%Q4 2022
ATRAAtara Biotherapeutics, Inc.$5.07M0.34%4.68%Not reportedQ4 2014
EPRXEupraxia Pharmaceuticals Inc.$4.04M0.27%1.18%-12.7%Q1 2026
ORICOric Pharmaceuticals, Inc.$3.92M0.26%0.35%-12.9%Q4 2025
ARDXArdelyx, Inc.$3.27M0.22%0.26%-12.5%Q4 2019
IVVDInvivyd, Inc.$2.27M0.15%0.88%-1.9%Q3 2021
PLRXPliant Therapeutics, Inc.$880K0.06%1.25%Not reportedQ2 2020
Q1 2026Reported May 15, 202635 positions
SRRKScholar Rock Holding Corp$446M29.51%7.61%+73.7%Q2 2018
KRYSKrystal Biotech, Inc.$174M11.52%2.29%-0.6%Q4 2018
STOKStoke Therapeutics, Inc.$136M8.98%6.69%+3.2%Q2 2019
IMNMImmunome Inc.$122M8.05%4.91%-2.8%Q4 2023
NRIXNurix Therapeutics, Inc.$120M7.94%7.48%-4.5%Q3 2020
ANNXAnnexon, Inc.$80.6M5.34%9.74%+44.8%Q3 2020
ADCTADC Therapeutics SA$58M3.84%12.17%-1.3%Q2 2020
RGNXREGENXBIO Inc.$36.6M2.42%8.46%Not reportedQ3 2015
STTKShattuck Labs, Inc.$35.6M2.36%7.33%Not reportedQ4 2020
BEAMBeam Therapeutics Inc.$29.5M1.95%1.20%-3.8%Q1 2020
NGNENeurogene Inc.$29.4M1.95%9.35%Not reportedQ4 2023
COGTCogent Biosciences, Inc.$26.5M1.75%0.40%-52.2%Q2 2023
ABSIAbsci Corp$24.8M1.64%5.39%Not reportedQ3 2021
IDYAIDEAYA Biosciences, Inc.$17.4M1.15%0.59%-29.8%Q4 2023
ALXOAlx Oncology Holdings Inc$16M1.06%5.76%+144.0%Q3 2020
FATEFate Therapeutics Inc$15.4M1.02%11.07%Not reportedQ2 2015
XENEXenon Pharmaceuticals Inc.$15.3M1.01%0.27%+96.2%Q2 2022
SLDBSolid Biosciences Inc.$14.5M0.96%2.04%+8.1%Q4 2024
NUVBNuvation Bio Inc.$13.5M0.90%0.91%-0.3%Q1 2021
ZYMEZymeworks Inc.$12.3M0.82%0.67%Not reportedQ1 2020
SLNSilence Therapeutics plc$11.4M0.76%1.53%Not reportedQ1 2024
DBVTDBV Technologies S.A.$10.3M0.68%0.17%-10.6%Q3 2015
BMRNBiomarin Pharmaceutical Inc$9.82M0.65%0.09%Not reportedQ2 2014
CLDXCelldex Therapeutics, Inc.$8.3M0.55%0.39%-7.7%Q4 2013
CBLLCeribell, Inc.$7.09M0.47%1.02%-11.1%Q4 2024
LIVNLivaNova PLC$6.89M0.46%0.20%-8.2%Q2 2017
ESTAEstablishment Labs Holdings Inc.$5.87M0.39%0.35%-8.2%Q3 2018
PRMEPrime Medicine, Inc.$5.54M0.37%0.88%Not reportedQ4 2022
ORICOric Pharmaceuticals, Inc.$5.27M0.35%0.40%-7.2%Q4 2025
EPRXEupraxia Pharmaceuticals Inc.$5.07M0.34%1.35%NewQ1 2026
ARDXArdelyx, Inc.$4.39M0.29%0.30%Not reportedQ4 2019
IVVDInvivyd, Inc.$3.44M0.23%0.94%-1.2%Q3 2021
ATRAAtara Biotherapeutics, Inc.$2.09M0.14%5.19%Not reportedQ4 2014
AGMBAgomab Therapeutics NV$1.64M0.11%0.46%NewQ1 2026
PLRXPliant Therapeutics, Inc.$973K0.06%1.25%-52.2%Q2 2020
Q4 2025Reported Feb 17, 202634 positions
SRRKScholar Rock Holding Corp$230M16.94%4.81%+33.7%Q2 2018
KRYSKrystal Biotech, Inc.$167M12.30%2.32%+2.5%Q4 2018
NRIXNurix Therapeutics, Inc.$154M11.31%7.95%+120.0%Q3 2020
STOKStoke Therapeutics, Inc.$128M9.43%6.85%-3.4%Q2 2019
IMNMImmunome Inc.$123M9.05%5.05%+13.8%Q4 2023
RGNXREGENXBIO Inc.$62.9M4.63%8.58%-6.9%Q3 2015
ADCTADC Therapeutics SA$55.3M4.07%12.46%Not reportedQ2 2020
COGTCogent Biosciences, Inc.$51.1M3.76%0.89%-34.9%Q2 2023
ANNXAnnexon, Inc.$50.5M3.72%6.73%+59.5%Q3 2020
BEAMBeam Therapeutics Inc.$35.6M2.62%1.26%-7.3%Q1 2020
NGNENeurogene Inc.$30.1M2.21%9.42%+12.4%Q4 2023
RAPTRAPT Therapeutics, Inc.$30M2.21%3.20%+60.3%Q1 2022
ABSIAbsci Corp$28.8M2.12%5.49%Not reportedQ3 2021
NUVBNuvation Bio Inc.$28.3M2.09%0.91%+4.4%Q1 2021
IDYAIDEAYA Biosciences, Inc.$25.7M1.89%0.85%Not reportedQ4 2023
STTKShattuck Labs, Inc.$20.2M1.49%8.75%Not reportedQ4 2020
SLNSilence Therapeutics plc$13.2M0.97%1.53%Not reportedQ1 2024
ZYMEZymeworks Inc.$12.9M0.95%0.66%-86.7%Q1 2020
FATEFate Therapeutics Inc$12.6M0.93%11.16%Not reportedQ2 2015
REPLReplimune Group, Inc.$10.7M0.79%1.38%+105.3%Q3 2018
DBVTDBV Technologies S.A.$10.5M0.78%0.33%Not reportedQ3 2015
SLDBSolid Biosciences Inc.$10.5M0.77%2.36%-2.0%Q4 2024
CBLLCeribell, Inc.$9.54M0.70%1.16%Not reportedQ4 2024
ESTAEstablishment Labs Holdings Inc.$8.21M0.60%0.38%-12.9%Q3 2018
ATRAAtara Biotherapeutics, Inc.$7.99M0.59%6.03%Not reportedQ4 2014
CLDXCelldex Therapeutics, Inc.$7.69M0.57%0.43%-13.4%Q4 2013
LIVNLivaNova PLC$7.26M0.53%0.22%-87.3%Q2 2017
IVVDInvivyd, Inc.$6.62M0.49%0.95%+17.3%Q3 2021
XENEXenon Pharmaceuticals Inc.$6M0.44%0.17%Not reportedQ2 2022
RPTXRepare Therapeutics Inc.$4.12M0.30%3.69%Not reportedQ2 2020
ALXOAlx Oncology Holdings Inc$3.69M0.27%6.00%-2.1%Q3 2020
ORICOric Pharmaceuticals, Inc.$3.67M0.27%0.45%NewQ4 2025
PLRXPliant Therapeutics, Inc.$1.97M0.15%2.63%+1.5%Q2 2020
KLRSKalaris Therapeutics, Inc.$700K0.05%0.36%Not reportedQ1 2025
Q3 2025Reported Nov 14, 202540 positions
SRRKScholar Rock Holding Corp$145M14.15%3.94%-0.6%Q2 2018
KRYSKrystal Biotech, Inc.$117M11.36%2.28%-0.3%Q4 2018
STOKStoke Therapeutics, Inc.$98.1M9.55%7.58%-4.6%Q2 2019
ZYMEZymeworks Inc.$63.3M6.16%4.93%-10.7%Q1 2020
ADCTADC Therapeutics SA$62.7M6.10%13.91%Not reportedQ2 2020
IMNMImmunome Inc.$58.8M5.72%5.48%+3.1%Q4 2023
LIVNLivaNova PLC$48.5M4.72%1.70%-0.8%Q2 2017
RGNXREGENXBIO Inc.$45.3M4.41%9.27%-1.7%Q3 2015
AKROAkero Therapeutics, Inc.$35.5M3.45%0.93%-3.4%Q2 2019
NRIXNurix Therapeutics, Inc.$34M3.31%4.78%-1.5%Q3 2020
BEAMBeam Therapeutics Inc.$33.7M3.28%1.37%-2.5%Q1 2020
COGTCogent Biosciences, Inc.$31.7M3.09%1.58%+52.6%Q2 2023
ABSIAbsci Corp$25.1M2.44%5.52%Not reportedQ3 2021
NGNENeurogene Inc.$22.5M2.19%8.79%+1.8%Q4 2023
ETNB89bio, Inc.$21.7M2.11%0.99%-4.7%Q1 2023
IDYAIDEAYA Biosciences, Inc.$20.2M1.96%0.85%+71.6%Q4 2023
ANNXAnnexon, Inc.$19.2M1.87%5.76%Not reportedQ3 2020
FATEFate Therapeutics Inc$16.2M1.58%11.16%Not reportedQ2 2015
RAPTRAPT Therapeutics, Inc.$14.3M1.39%3.34%-12.4%Q1 2022
STTKShattuck Labs, Inc.$13.2M1.29%8.77%Not reportedQ4 2020
SLDBSolid Biosciences Inc.$11.7M1.14%2.44%-0.9%Q4 2024
SLNSilence Therapeutics plc$11.2M1.09%1.53%Not reportedQ1 2024
NUVBNuvation Bio Inc.$11.2M1.09%0.90%Not reportedQ1 2021
KROSKeros Therapeutics, Inc.$8.74M0.85%1.36%Not reportedQ1 2024
CLDXCelldex Therapeutics, Inc.$8.46M0.82%0.49%-4.7%Q4 2013
ATRAAtara Biotherapeutics, Inc.$6.33M0.62%6.13%Not reportedQ4 2014
FOLDAmicus Therapeutics, Inc.$6.12M0.60%0.25%-34.6%Q1 2013
ALXOAlx Oncology Holdings Inc$6.1M0.59%6.22%-1.7%Q3 2020
ESTAEstablishment Labs Holdings Inc.$5.3M0.52%0.45%-5.2%Q3 2018
CBLLCeribell, Inc.$5M0.49%1.17%Not reportedQ4 2024
XERSXeris Biopharma Holdings, Inc.$3.67M0.36%0.27%Not reportedQ2 2018
VTYXVentyx Biosciences, Inc.$3.34M0.32%1.50%-3.7%Q3 2022
LVTXLAVA Therapeutics NV$3.24M0.31%7.89%Not reportedQ1 2021
RPTXRepare Therapeutics Inc.$2.79M0.27%3.69%Not reportedQ2 2020
IVVDInvivyd, Inc.$2.51M0.24%1.07%Not reportedQ3 2021
PLRXPliant Therapeutics, Inc.$2.36M0.23%2.59%-2.5%Q2 2020
REPLReplimune Group, Inc.$2.25M0.22%0.68%-88.5%Q3 2018
PRMEPrime Medicine, Inc.$483K0.05%0.05%-95.8%Q4 2022
KLRSKalaris Therapeutics, Inc.$479K0.05%0.44%Not reportedQ1 2025
BOLDBoundless Bio, Inc.$302K0.03%1.10%-58.3%Q1 2024
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.